AU2002320122A1 - Sustained release formulation - Google Patents

Sustained release formulation

Info

Publication number
AU2002320122A1
AU2002320122A1 AU2002320122A AU2002320122A AU2002320122A1 AU 2002320122 A1 AU2002320122 A1 AU 2002320122A1 AU 2002320122 A AU2002320122 A AU 2002320122A AU 2002320122 A AU2002320122 A AU 2002320122A AU 2002320122 A1 AU2002320122 A1 AU 2002320122A1
Authority
AU
Australia
Prior art keywords
sustained release
release formulation
formulation
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002320122A
Other versions
AU2002320122B2 (en
Inventor
Jeffrey L. Cleland
Franklin Okumu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30027501P priority Critical
Priority to US60/300,275 priority
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to PCT/US2002/019597 priority patent/WO2003000282A1/en
Priority to US10/176,961 priority
Priority to US10/176,961 priority patent/US7318931B2/en
Publication of AU2002320122A1 publication Critical patent/AU2002320122A1/en
Application granted granted Critical
Publication of AU2002320122B2 publication Critical patent/AU2002320122B2/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2002320122A 2001-06-21 2002-06-21 Sustained release formulation Active AU2002320122B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US30027501P true 2001-06-21 2001-06-21
US60/300,275 2001-06-21
PCT/US2002/019597 WO2003000282A1 (en) 2001-06-21 2002-06-21 Sustained release formulation
US10/176,961 2002-06-21
US10/176,961 US7318931B2 (en) 2001-06-21 2002-06-21 Sustained release formulation

Publications (2)

Publication Number Publication Date
AU2002320122A1 true AU2002320122A1 (en) 2003-06-19
AU2002320122B2 AU2002320122B2 (en) 2007-07-26

Family

ID=26872798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320122A Active AU2002320122B2 (en) 2001-06-21 2002-06-21 Sustained release formulation

Country Status (10)

Country Link
US (2) US7318931B2 (en)
EP (1) EP1397155B1 (en)
JP (2) JP4460892B2 (en)
AU (1) AU2002320122B2 (en)
CA (1) CA2448218C (en)
DK (1) DK1397155T3 (en)
ES (1) ES2554106T3 (en)
IL (1) IL159048D0 (en)
PT (1) PT1397155E (en)
WO (1) WO2003000282A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1397155T3 (en) * 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR20050071498A (en) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 Ghrh analogues
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE60334401D1 (en) 2002-12-13 2010-11-11 Durect Corp Oral pharmaceutical form with liquid high viscosive carrier systems
DE10312346A1 (en) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Controlled release system
AU2004227837A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
EP1620072B1 (en) * 2003-05-01 2008-03-26 LTT Bio-Pharma Co., Ltd. Zinc-containing sustained-release composition, its preparation, and method for producing the same
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2551082A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. Hiv gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EA014852B1 (en) * 2004-09-17 2011-02-28 Дьюрект Корпорейшн Controlled delivery system
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007016380A2 (en) * 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate
JP4682251B2 (en) * 2006-02-02 2011-05-11 トリメリス,インコーポレーテッド HIV fusion inhibitor peptides with improved biological properties
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
PL2117521T3 (en) 2006-11-03 2012-11-30 Transdermal delivery systems comprising bupivacaine
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20090068243A1 (en) * 2007-04-03 2009-03-12 Brian Bray Novel formulations for delivery of antiviral peptide therapeutics
JP5351884B2 (en) 2007-04-23 2013-11-27 インターシア セラピューティクス,インコーポレイティド Suspension preparation and use of insulin secretagogue peptide
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
MX2010003179A (en) * 2007-09-25 2010-04-30 Trimeris Inc Methods of synthesis for therapeuthic anti-hiv peptides.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2706931C (en) * 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US20090202481A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5599778B2 (en) 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシーDePuy Synthes Products, LLC Liquid buffered GDF-5 formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP2012510468A (en) * 2008-11-28 2012-05-10 アボット・ラボラトリーズAbbott Laboratories Stable antibody composition and method for stabilizing the same
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
NZ624569A (en) 2009-09-28 2016-01-29 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011112996A2 (en) * 2010-03-12 2011-09-15 Surmodics, Inc. Injectable drug delivery system
CA2808626A1 (en) 2010-08-18 2012-02-23 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
BR112014009866A2 (en) 2011-10-25 2018-09-04 Onclave Therapeutics Ltd antibody formulations and methods
KR20150018765A (en) 2012-01-20 2015-02-24 데니스 브라운 Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JP2016515523A (en) 2013-03-15 2016-05-30 デュレクト コーポレーション Compositions having rheology modifiers to reduce dissolution variability
CN105764501A (en) 2013-07-26 2016-07-13 现代化制药公司 Compositions to improve the therapeutic benefit of bisantrene
JP6476540B2 (en) * 2013-10-08 2019-03-06 株式会社リコー Display device, display system, and program
WO2015058868A1 (en) 2013-10-25 2015-04-30 Pangaea Biotech, S.L. Compositions and methods for the treatment of cancer
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456433A (en) 1973-06-25 1976-11-24 Quaker Oats Co Semi-moist cat food
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
DE2916711A1 (en) 1979-04-25 1980-11-06 Behringwerke Ag Blood clotting factors and methods for their production
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
JPH0482040B2 (en) 1986-05-02 1992-12-25 Kao Corp
WO1989003671A1 (en) 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0223866A (en) 1988-07-11 1990-01-26 Kikkoman Corp Stabilization of sucrose phosphorylase
FR2634121B1 (en) 1988-07-13 1992-05-07 Imedex Process for the preparation of collagen microparticles and products obtained
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5114929A (en) 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
SE465950B (en) 1989-10-23 1991-11-25 Medinvent Sa Combination of an aggregate particulate, crystalline or freeze-dried laekemedel with a pseudoplastic gel foer preparation of an injectable preparation and foerfarande foer its framstaellning
US5133981A (en) 1989-11-17 1992-07-28 Atrix Laboratories, Inc. Purification of benzophenanthridine alkaloids extracts from alkaloid extracts
ZA9108526B (en) 1990-10-30 1992-08-26 Alza Corp Drug delivery system and method
JPH04271785A (en) 1991-02-28 1992-09-28 Kao Corp Enzymic solid pharmaceutical and its production
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0831786A2 (en) 1995-06-07 1998-04-01 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
AT195652T (en) 1992-12-02 2000-09-15 Alkermes Inc Growth hormone-containing microsphere controlled-release
DK0831787T3 (en) 1995-06-07 2001-12-17 Alkermes Inc A composition for the sustained release of human growth hormone
DE69426292D1 (en) * 1993-02-23 2000-12-21 Genentech Inc Stabilization of polypeptides treated with organic solvent with an excipient
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US6080429A (en) 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
JP3125610B2 (en) 1993-12-24 2001-01-22 和光純薬工業株式会社 Stabilization Act of L- methionine γ- lyase
EP0668073B1 (en) 1994-02-21 1999-04-14 Takeda Chemical Industries, Ltd. Polyester matrix for a pharmaceutical sustained-release preparation
US5556905A (en) 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
DE69524398D1 (en) 1994-04-08 2002-01-17 Atrix Lab Inc Cash and cash equivalents for drug donation
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
JP4330175B2 (en) 1995-06-07 2009-09-16 デュレクト コーポレイション Controlled delivery system with high viscosity liquid
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5851229A (en) * 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
DE69730093T2 (en) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Preparation with delayed release
US6130200A (en) 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
KR20000057693A (en) 1996-12-20 2000-09-25 다케다 야쿠힌 고교 가부시키가이샤 Method of producing a sustained-release preparation
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
JPH11158200A (en) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Human growth hormone/zinc complex and its use
US6039977A (en) 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
US6328979B1 (en) 1997-12-26 2001-12-11 Yamanouchi Pharmaceuticals, Co. Ltd. Sustained release medicinal compositions
DE19813010A1 (en) 1998-03-25 1999-10-14 Aventis Res & Tech Gmbh & Co Microcapsules with delayed release
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DK1140018T3 (en) * 1998-12-23 2004-02-02 Amgen Inc Polyol / oil suspensions for the sustained release of proteins
EP1060741B1 (en) 1999-06-14 2003-09-03 Baxter Healthcare SA Sustained release microspheres
WO2000078335A1 (en) 1999-06-18 2000-12-28 Southern Biosystems, Inc. COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE60115005T2 (en) 2000-04-19 2006-07-27 Durect Corp., Cupertino Formulations with delayed release containing growth hormone
MXPA03000073A (en) 2000-06-26 2003-09-25 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin.
DK1397155T3 (en) 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
GB2403086B (en) 2003-06-17 2005-07-20 Motorola Inc Cartesian loop transmitter and method of adjusting an output level of such transmitter
WO2012137071A2 (en) * 2011-04-06 2012-10-11 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Similar Documents

Publication Publication Date Title
AU2002313952A1 (en) Concatameric immunoadhesion
AU2002355055A1 (en) Polyelectrolyte compositions
AU2003298738A1 (en) Liposomal formulations
AU2002246336A1 (en) Benzamidine derivative
AU2002323381A1 (en) Deodorant composition
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002300377A1 (en) Compositions for controlled release
AU2002227383A1 (en) Controlled Release Hydrocodone Formulations
AU2002361585A1 (en) Nanostructured compositions
AU2002338914A1 (en) Cosmetic agents
AU2002313236A1 (en) Medicinal compositions
AU2002363250A1 (en) Pyrazole-amides and-sulfonamides
AU2002337489A1 (en) Inexsufflator
AU2002330164A1 (en) Modified release dosage forms
AU2002314714A1 (en) Antimicrobial formulations
AU2002242024A1 (en) Pharmaceutical formulation
AU2002337498A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002303614A1 (en) Once-a-day oxycodone formulations
AU2002359163A1 (en) New use
AU2003225125A1 (en) Fragrance release
AU2002241888A1 (en) Selectively-operative one-way clutcher
AU2002244314A1 (en) Modification of the sustained release profile
AU2002327068A1 (en) Immediate release tablet
AU2002337499A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002258563A1 (en) Pharmaceutical formulations for sustained release